All In Biotech

Drug Trial Radar · NCT06165822

A Study to Evaluate Drug-Drug Interaction of TQB3909 Tablets

A Phase I Study to Evaluate Drug-Drug Interaction of TQB3909 Tablets

Last checked: Nov 19, 2026Latest source record: Dec 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

40

Planned (sponsor's estimate)

Start

Dec 2023

Primary completion

Jan 2024

Study completion Mar 2024

Sponsor

Sponsor type
Industry
First posted
Dec 12, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a single-center, open, single-dose, self-controlled phase I clinical trial to evaluate the effects of Itraconazole Capsules/Rifampicin Capsules on pharmacokinetics of TQB3909 tablets in vivo, and the safety of TQB3909 tablets and combined with Itraconazole Capsules/Rifampicin Capsules after single oral dose.

Conditions

  • Advanced Malignant Neoplasm

Interventions

  • TQB3909 tabletsDrug

    TQB3909 100mg/tablet.

  • Itraconazole capsuleDrug

    Itraconazole capsule is a strong inhibitor of CYP3A4.

  • Rifampicin capsuleDrug

    Rifampicin capsule is a strong inducer of CYP3A4.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Reach Maximum Observed Plasma Concentration (Tmax)Time frame: Inhibitor group: pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 14, 24, 48, 72 hours (only on Day 8) after dose on Day 1 and Day 8. Inducer group: pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 14, 24, 48 hours after dose on Day 1 and Day 10.
  2. Maximum Plasma Concentration (Cmax)Time frame: Inhibitor group: pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 14, 24, 48, 72 hours (only on Day 8) after dose on Day 1 and Day 8. Inducer group: pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 14, 24, 48 hours after dose on Day 1 and Day 10.
  3. Elimination half-life (t1/2)Time frame: Inhibitor group: pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 14, 24, 48, 72 hours (only on Day 8) after dose on Day 1 and Day 8. Inducer group: pre-dose, 1, 2, 3, 4, 5, 6, 7, 8, 10, 14, 24, 48 hours after dose on Day 1 and Day 10.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First People's Hospital of Changzhou

    Changzhou, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.